Loading
Anyone with ovarian, pancreatic, metastatic prostate or mismatch-repair-deficient colorectal cancer should be tested for inherited mutations, yet testing rates fall well short. Making it an automatic, opt-out laboratory step triggered by pathology, as reflex mismatch-repair testing already is, would close the gap.
Anyone with ovarian, pancreatic, metastatic prostate or mismatch-repair-deficient colorectal cancer should have germline testing, but testing rates fall well short, so this idea makes it an automatic opt-out laboratory step triggered by pathology, as reflex MMR and MSI testing already is, mainstreamed by oncologists with genetics support only for positives. Reflex mismatch-repair testing succeeded and mainstreaming trials show oncologists can consent patients. The aim is near-universal testing in eligible groups and proportionally more cascade testing of relatives. The test is health-system implementation with monthly testing-rate dashboards. Being tested at scale, it addresses the bottleneck Inherited risk is mostly unidentified.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
The evidence that made germline testing standard for every man with metastatic prostate cancer, whatever his family history. It changes his treatment, because PARP inhibitors and platinum work better in these tumours, and it changes his relatives' screening, because BRCA2 carries breast, ovarian and pancreatic risk as well.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Early-onset colorectal cancer (under 50), Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Germline vs somatic mutations, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Germline vs somatic mutations, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing, Ovarian cancer.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Germline (hereditary) testing.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).